✦ LIBER ✦

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

✍ Scribed by Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; Beslija, Semir; Stemmer, Salomon M; Kaufman, Bella; Zvirbule, Zanete; Steger, Günther G; Melichar, Bohuslav; Pienkowski, Tadeusz; Sirbu, Daniela; Messinger, Diethelm; Zielinski, Christoph

Book ID: 120036953
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 420 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(12)70566-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of bevacizumab plus paclita

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

✍ Wang, Xuan; Huang, Chun; Li, Man; Gu, Yanjun; Cui, Yanfen; Li, Yan 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 395 KB

Biomarker results from the AVADO phase 3

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

✍ Miles, D W; de Haas, S L; Dirix, L Y; Romieu, G; Chan, A; Pivot, X; Tomczak, P; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 366 KB

S-1 plus oxaliplatin versus capecitabine

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

✍ Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo K 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 200 KB

Capecitabine plus paclitaxel versus epir

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB